Niraparib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Niraparib comprises 195 peer-reviewed publications across 15 journals, 20 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Ovarian Neoplasms, Breast Neoplasms, Glioma, and Neoplasms. Most recent publication: Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study., Int J Urol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Global cancer statistics, 2012.
    Torre LA, Bray F, Siegel RL, et al. · CA Cancer J Clin · 2015
    PubMed: PMID 25651787 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  2. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, et al. · Breast Cancer Res Treat · 2012
    PubMed: PMID 21796368 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
    Kirstein MM, Lange A, Prenzler A, et al. · Oncologist · 2015
    PubMed: PMID 25326159 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  4. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, et al. · Radiology · 2012
    PubMed: PMID 22623692 · NCT01042379 (I-SPY) · Breast Neoplasms
  5. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.
    Fakhrejahani E, Toi M · Jpn J Clin Oncol · 2014
    PubMed: PMID 24474817 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  6. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN, Tewari KS · Clin Ther · 2016
    PubMed: PMID 25592089 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  7. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.
    Chu JS, Ge FJ, Zhang B, et al. · J Exp Clin Cancer Res · 2013
    PubMed: PMID 23552472 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  8. [Report of Cancer Incidence and Mortality in China, 2014].
    Chen WQ, Li H, Sun KX, et al. · Zhonghua Zhong Liu Za Zhi · 2018
    PubMed: PMID 29365411 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01847274Ovarian NeoplasmsProgression-Free Survival (PFS) in Cohort With Germline BReast CAncer Gene (BRCA) Mutation (gBRCA)
From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years 7 months and 4 days
gBRCA Niraparib21 months
gBRCA Placebo5.5 months
NCT01847274Ovarian NeoplasmsProgression-Free Survival (PFS) in Cohort With No Germline BCRA With Homologous Recombination Deficiency-positive (HRD+) Tumors (Non-gBRCAmut HRD+)
From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days
Non-gBRCAmut HRD+ Niraparib12.9 months
Non-gBRCAmut HRD+ Placebo3.8 months
NCT01847274Ovarian NeoplasmsProgression-Free Survival (PFS) in Cohort With No Germline BRCA Mutation
From date of randomization to the earliest date of disease progression or death from any cause, up to 7 years, 7 months and 4 days
Non-gBRCA Niraparib9.3 Months
Non-gBRCA Placebo3.9 Months
NCT01905592
BRAVO
Ovarian NeoplasmsProgression Free Survival (PFS) - Central Review Assessment
From the date of randomization to the date of disease progression or death due to any cause, whichever occurs earlier, up to 4 years
Niraparib4.1 Months
Physician's Choice3.1 Months
NCT02655016Ovarian NeoplasmsProgression Free Survival
Up to 34 months
Niraparib13.8 Months
Placebo8.2 Months
NCT03602859
FIRST
Ovarian NeoplasmsProgression Free Survival (PFS)
Up to approximately 316 weeks
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)20.63 Months
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)19.19 Months
NCT03748641
MAGNITUDE
Prostatic Neoplasms, Castration-ResistantCohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Up to 32 months
Cohort 1 BRCA Subgroup: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg16.56 Months
Cohort 1 BRCA Subgroup: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg10.87 Months
NCT03748641
MAGNITUDE
Prostatic Neoplasms, Castration-ResistantCohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Up to 32 months
Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg16.46 Months
Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg13.70 Months
NCT04475939
ZEAL-1L
Carcinoma, Non-Small-Cell LungProgression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population
Up to 52 months
Niraparib + Pembrolizumab5.55 Months
Placebo + Pembrolizumab5.55 Months
NCT04497844
AMPLITUDE
—All HRR: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
From date of randomization (Day -3 to Day 1) up to approximately 49 months
Niraparib With Abiraterone Acetate Plus PrednisoneNA months
Placebo With Abiraterone Acetate Plus Prednisone29.54 months
NCT04497844
AMPLITUDE
—Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
From date of randomization (Day -3 to Day 1) up to approximately 49 months
BRCA Subgroup: Niraparib With Abiraterone Acetate Plus PrednisoneNA months
BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone25.99 months
NCT04497844
AMPLITUDE
—HRR Effector Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator
From date of randomization (Day -3 to Day 1) up to approximately 49 months
HRR Effector Subgroup: Niraparib With Abiraterone Acetate Plus PrednisoneNA months
HRR Effector Subgroup: Placebo With Abiraterone Acetate Plus Prednisone27.56 months
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
Up to approximately 125 weeks
Niraparib16 Participants
Niraparib1 Participants
Niraparib9 Participants
Niraparib17 Participants
Niraparib2 Participants
Niraparib0 Participants
Niraparib7 Participants
Niraparib2 Participants
Placebo4 Participants
Placebo11 Participants
Placebo6 Participants
Placebo17 Participants
Placebo0 Participants
Placebo9 Participants
Placebo1 Participants
Placebo16 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With TEAEs Leading to Death
Up to approximately 125 weeks
Niraparib0 Participants
Placebo0 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With TEAEs Leading to Dose Modifications and Discontinuation of Study Treatment
Up to approximately 125 weeks
Niraparib10 Participants
Niraparib11 Participants
Niraparib0 Participants
Placebo0 Participants
Placebo0 Participants
Placebo1 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With Treatment Emergent Adverse Event (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Up to approximately 125 weeks
Niraparib5 Participants
Niraparib18 Participants
Niraparib0 Participants
Placebo1 Participants
Placebo0 Participants
Placebo17 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With Use of Concomitant Medications
Up to approximately 125 weeks
Niraparib18 Participants
Placebo18 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With Worst-Case Post-Baseline (WCPB) Clinical Chemistry Results Relative to Baseline
Up to approximately 125 weeks
Niraparib2 Participants
Niraparib1 Participants
Niraparib2 Participants
Niraparib4 Participants
Niraparib0 Participants
Niraparib8 Participants
Niraparib0 Participants
Niraparib0 Participants
Niraparib12 Participants
Niraparib6 Participants
Niraparib13 Participants
Niraparib5 Participants
Niraparib6 Participants
Niraparib2 Participants
Niraparib14 Participants
Niraparib2 Participants
Niraparib3 Participants
Niraparib12 Participants
Niraparib3 Participants
Niraparib0 Participants
Niraparib4 Participants
Niraparib0 Participants
Niraparib4 Participants
Niraparib11 Participants
Niraparib3 Participants
Niraparib1 Participants
Niraparib0 Participants
Niraparib2 Participants
Niraparib0 Participants
Niraparib5 Participants
Niraparib10 Participants
Niraparib0 Participants
Niraparib1 Participants
Niraparib2 Participants
Niraparib3 Participants
Niraparib1 Participants
Niraparib14 Participants
Niraparib3 Participants
Niraparib1 Participants
Niraparib11 Participants
Niraparib6 Participants
Niraparib3 Participants
Niraparib13 Participants
Niraparib2 Participants
Niraparib2 Participants
Niraparib5 Participants
Niraparib0 Participants
Niraparib0 Participants
Niraparib8 Participants
Niraparib1 Participants
Niraparib0 Participants
Niraparib3 Participants
Niraparib0 Participants
Niraparib7 Participants
Niraparib11 Participants
Niraparib1 Participants
Niraparib2 Participants
Niraparib12 Participants
Niraparib1 Participants
Niraparib6 Participants
Niraparib11 Participants
Niraparib0 Participants
Niraparib12 Participants
Niraparib6 Participants
Niraparib1 Participants
Niraparib15 Participants
Placebo19 Participants
Placebo1 Participants
Placebo15 Participants
Placebo5 Participants
Placebo3 Participants
Placebo18 Participants
Placebo0 Participants
Placebo0 Participants
Placebo16 Participants
Placebo4 Participants
Placebo0 Participants
Placebo7 Participants
Placebo0 Participants
Placebo0 Participants
Placebo18 Participants
Placebo3 Participants
Placebo1 Participants
Placebo9 Participants
Placebo3 Participants
Placebo3 Participants
Placebo18 Participants
Placebo0 Participants
Placebo0 Participants
Placebo18 Participants
Placebo3 Participants
Placebo0 Participants
Placebo4 Participants
Placebo0 Participants
Placebo3 Participants
Placebo14 Participants
Placebo4 Participants
Placebo1 Participants
Placebo17 Participants
Placebo2 Participants
Placebo0 Participants
Placebo13 Participants
Placebo2 Participants
Placebo2 Participants
Placebo13 Participants
Placebo6 Participants
Placebo0 Participants
Placebo4 Participants
Placebo0 Participants
Placebo1 Participants
Placebo7 Participants
Placebo0 Participants
Placebo0 Participants
Placebo10 Participants
Placebo0 Participants
Placebo2 Participants
Placebo16 Participants
Placebo3 Participants
Placebo2 Participants
Placebo17 Participants
Placebo1 Participants
Placebo1 Participants
Placebo1 Participants
Placebo1 Participants
Placebo6 Participants
Placebo0 Participants
Placebo1 Participants
Placebo13 Participants
Placebo1 Participants
Placebo1 Participants
Placebo3 Participants
Placebo1 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With Worst-Case Post-Baseline (WCPB) Hematology Results Relative to Baseline
Up to approximately 125 weeks
Niraparib9 Participants
Niraparib12 Participants
Niraparib9 Participants
Niraparib1 Participants
Niraparib9 Participants
Niraparib3 Participants
Niraparib5 Participants
Niraparib10 Participants
Niraparib10 Participants
Niraparib8 Participants
Niraparib1 Participants
Niraparib1 Participants
Niraparib9 Participants
Niraparib8 Participants
Niraparib3 Participants
Niraparib8 Participants
Niraparib7 Participants
Niraparib4 Participants
Niraparib3 Participants
Niraparib12 Participants
Niraparib9 Participants
Niraparib9 Participants
Niraparib13 Participants
Niraparib4 Participants
Niraparib9 Participants
Niraparib0 Participants
Niraparib0 Participants
Niraparib1 Participants
Niraparib0 Participants
Niraparib4 Participants
Placebo0 Participants
Placebo0 Participants
Placebo21 Participants
Placebo21 Participants
Placebo1 Participants
Placebo1 Participants
Placebo2 Participants
Placebo1 Participants
Placebo19 Participants
Placebo15 Participants
Placebo2 Participants
Placebo3 Participants
Placebo0 Participants
Placebo0 Participants
Placebo16 Participants
Placebo19 Participants
Placebo6 Participants
Placebo1 Participants
Placebo1 Participants
Placebo21 Participants
Placebo0 Participants
Placebo2 Participants
Placebo14 Participants
Placebo6 Participants
Placebo1 Participants
Placebo2 Participants
Placebo15 Participants
Placebo17 Participants
Placebo6 Participants
Placebo1 Participants
NCT04915755
ZEST
Breast NeoplasmsNumber of Participants With Worst-Case Post-Baseline (WCPB) Vital Signs Results Relative to Baseline
Up to approximately 125 weeks
Niraparib0 Participants
Niraparib13 Participants
Niraparib18 Participants
Niraparib9 Participants
Niraparib5 Participants
Niraparib0 Participants
Niraparib0 Participants
Niraparib1 Participants
Niraparib12 Participants
Niraparib6 Participants
Niraparib8 Participants
Niraparib0 Participants
Placebo0 Participants
Placebo0 Participants
Placebo0 Participants
Placebo1 Participants
Placebo16 Participants
Placebo21 Participants
Placebo2 Participants
Placebo21 Participants
Placebo4 Participants
Placebo0 Participants
Placebo22 Participants
Placebo0 Participants

Publications by year

2001–2026: 195 publications.

2001
1
2003
1
2005
1
2008
1
2009
1
2010
1
2011
3
2012
5
2013
3
2014
2
2015
5
2016
7
2017
8
2018
5
2019
8
2020
10
2021
23
2022
27
2023
27
2024
31
2025
17
2026
8

Publications by indication

Ovarian Neoplasms (62)

  • Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    JAMA Oncol · 2026 · PMID 31194225 · NCT02657889
  • Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).
    Eur J Cancer · 2026 · PMID 41950571 · NCT03891576
  • Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol · 2026 · PMID 37597580 · NCT06827353
  • Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).
    JNCI Cancer Spectr · 2025 · PMID 39673810 · NCT03752216
  • Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis.
    Redox Biol · 2025 · PMID 39922130 · NCT04507841

Breast Neoplasms (37)

  • Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Radiol Artif Intell · 2026 · PMID 41879562 · NCT01042379
  • Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    NPJ Breast Cancer · 2026 · PMID 36456573 · NCT01042379
  • Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Front Oncol · 2026 · PMID 40777112 · NCT01042379
  • Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    JCO Precis Oncol · 2025 · PMID 40526879 · NCT01042379
  • Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Breast Cancer Res Treat · 2025 · PMID 39625569 · NCT01042379

Glioma (22)

  • A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
    Oncotarget · 2023 · PMID 30647846 · NCT06258018
  • Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
    Sci Adv · 2022 · PMID 32494639 · NCT06258018
  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
    Nat Rev Clin Oncol · 2021 · PMID 33293629 · NCT06258018
  • Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review.
    J Am Coll Cardiol · 2021 · PMID 34045027 · NCT06258018
  • A therapeutic update on PARP inhibitors: implications in the treatment of glioma.
    Drug Discov Today · 2021 · PMID 33157194 · NCT06258018

Neoplasms (16)

  • Prospective evaluation of genomics-guided off-label treatment.
    Nature · 2026 · PMID 41986720 · NCT02925234
  • Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
    Int J Gynecol Cancer · 2025 · PMID 39322611 · NCT03981796
  • A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
    Future Oncol · 2025 · PMID 38990090 · NCT03981796
  • Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Clin Cancer Res · 2024 · PMID 38630551 · NCT02925234
  • Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study.
    BMJ Open · 2024 · PMID 39581729 · NCT03981796

Endometrial Neoplasms (16)

  • Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study.
    Cancer · 2025 · PMID 40445839 · NCT04178460
  • PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium.
    Int J Gynecol Pathol · 2023 · PMID 35443252 · NCT04080284
  • An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Gynecol Oncol · 2021 · PMID 32988624 · NCT05289648
  • Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
    Clin Cancer Res · 2020 · PMID 30413523 · NCT05289648
  • Clinical actionability of molecular targets in endometrial cancer.
    Nat Rev Cancer · 2019 · PMID 31388127 · NCT05289648

Uterine Cervical Neoplasms (7)

  • [Report of Cancer Incidence and Mortality in China, 2014].
    Zhonghua Zhong Liu Za Zhi · 2018 · PMID 29365411 · NCT04395612
  • Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Clin Ther · 2016 · PMID 25592089 · NCT04395612
  • Global cancer statistics, 2012.
    CA Cancer J Clin · 2015 · PMID 25651787 · NCT04395612
  • Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
    Oncologist · 2015 · PMID 25326159 · NCT04395612
  • Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.
    Jpn J Clin Oncol · 2014 · PMID 24474817 · NCT04395612

Publications by journal

Trial-results highlights

In the NCT01847274 study for ovarian neoplasms, median Progression-Free Survival (PFS) was observed across different patient groups. For patients with a germline BRCA mutation (gBRCA), the Niraparib arm reported a median PFS of 21 months, while the placebo arm reported 5.5 months. In patients without a germline BRCA mutation but with Homologous Recombination Deficiency-positive (HRD+) tumors (Non-gBRCAmut HRD+), the Niraparib arm showed a median PFS of 12.9 months, compared to 3.8 months in the placebo arm. For the overall group of patients without a germline BRCA mutation (Non-gBRCA), the Niraparib arm had a median PFS of 9.3 months, and the placebo arm had 3.9 months.

Further studies also investigated Niraparib in ovarian neoplasms. In the NCT01905592 (BRAVO) study, median Progression-Free Survival (PFS) was 4.1 months for the Niraparib arm and 3.1 months for the Physician's Choice arm. The NCT02655016 study reported a median PFS of 13.8 months for the Niraparib arm and 8.2 months for the placebo arm. In the NCT03602859 (FIRST) study, the arm receiving Paclitaxel + Carboplatin + Dostarlimab +/- Bev, then Niraparib+Dostarlimab +/- Bev (Arm3) had a median PFS of 20.63 months, while the arm receiving Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) had 19.19 months.

For prostatic neoplasms that are castration-resistant, the NCT03748641 (MAGNITUDE) study examined Niraparib in combination therapy. In Cohort 1's BRCA subgroup, the median radiographic Progression-Free Survival (rPFS) was 16.56 months for the arm receiving Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg, compared to 10.87 months for the arm receiving Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg. For the overall Cohort 1, the arm receiving Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg reported a median rPFS of 16.46 months, versus 13.70 months for the arm receiving Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg.

All reported values are sourced from primary clinical trial registry reporting; individual scientific publications should be consulted for detailed clinical data and decision-making.

All Niraparib publications (195)

2026 (8 papers)

  1. Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.
    Ye D, Saad M, Lee JY, et al. · Int J Urol · 2026 · Derived
    PubMed: PMID 42015879 · NCT03748641 (MAGNITUDE) · Prostatic Neoplasms, Castration-Resistant
  2. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
    Vinayak S, Tolaney SM, Schwartzberg L, et al. · JAMA Oncol · 2026 · Derived
    PubMed: PMID 31194225 · NCT02657889 (TOPACIO) · Ovarian Neoplasms
  3. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  4. Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Teng X, Ma J, Zhang J, et al. · Radiol Artif Intell · 2026 · Derived
    PubMed: PMID 41879562 · NCT01042379 (I-SPY) · Breast Neoplasms
  5. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, et al. · NPJ Breast Cancer · 2026 · Derived
    PubMed: PMID 36456573 · NCT01042379 (I-SPY) · Breast Neoplasms
  6. Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Hensley M, Lengfeld J, Stoesz S, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 40777112 · NCT01042379 (I-SPY) · Breast Neoplasms
  7. Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).
    Colombo N, Parma G, Tasca G, et al. · Eur J Cancer · 2026 · Derived
    PubMed: PMID 41950571 · NCT03891576 (Newton) · Ovarian Neoplasms
  8. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    González-Martín A, Harter P, Leary A, et al. · Ann Oncol · 2026 · Background
    PubMed: PMID 37597580 · NCT06827353 (OVNI-B) · Ovarian Neoplasms

2025 (17 papers)

  1. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40526879 · NCT01042379 (I-SPY) · Breast Neoplasms
  2. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
    Valabrega G, Powell MA, Hietanen S, et al. · Int J Gynecol Cancer · 2025 · Derived
    PubMed: PMID 39322611 · NCT03981796 (RUBY) · Neoplasms
  3. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, et al. · Breast Cancer Res Treat · 2025 · Derived
    PubMed: PMID 39625569 · NCT01042379 (I-SPY) · Breast Neoplasms
  4. Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.
    Rathkopf DE, Roubaud G, Chi KN, et al. · Eur Urol · 2025 · Derived
    PubMed: PMID 39317633 · NCT03748641 (MAGNITUDE) · Prostatic Neoplasms, Castration-Resistant
  5. Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study.
    Qiu MZ, Pan H, Lam KO, et al. · Cancer · 2025 · Derived
    PubMed: PMID 40445839 · NCT04178460 · Endometrial Neoplasms
  6. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer".
    Mirza MR, Chase DM, Slomovitz BM, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 38990090 · NCT03981796 (RUBY) · Neoplasms
  7. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, et al. · Breast Cancer Res · 2025 · Derived
    PubMed: PMID 40551254 · NCT01042379 (I-SPY) · Breast Neoplasms
  8. Phase II Study of Niraparib in Patients With Advanced Melanoma With Homologous Recombination Pathway Gene Mutations.
    Kim KB, Desprez PY, de Semir D, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40373259 · NCT03925350 · Melanoma
  9. Improving real-world evaluation of patient- and physician-reported tolerability: niraparib for recurrent ovarian cancer (NiQoLe).
    Joly F, Bazan F, Garbay D, et al. · JNCI Cancer Spectr · 2025 · Derived
    PubMed: PMID 39673810 · NCT03752216 (NiQoLe) · Ovarian Neoplasms
  10. A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images.
    Jing B, Wang J · Phys Med Biol · 2025 · Derived
    PubMed: PMID 40639409 · NCT01042379 (I-SPY) · Breast Neoplasms
  11. Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis.
    Jin N, Qian YY, Jiao XF, et al. · Redox Biol · 2025 · Derived
    PubMed: PMID 39922130 · NCT04507841 · Ovarian Neoplasms
  12. Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma.
    Hatoum F, Souza GR, Johnson J, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 41163621 · NCT05526989 · Penile Neoplasms
  13. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
    Hardesty MM, Krivak TC, Wright GS, et al. · Gynecol Oncol · 2025 · Derived
    PubMed: PMID 40602355 · NCT03326193 · Ovarian Neoplasms
  14. Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
    Gilad M, Partridge SC, Iima M, et al. · Radiol Imaging Cancer · 2025 · Derived
    PubMed: PMID 40679371 · NCT01042379 (I-SPY) · Breast Neoplasms
  15. Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.
    Deng T, Yan L, Li J, et al. · Ther Clin Risk Manag · 2025 · Derived
    PubMed: PMID 40718116 · NCT04376073 (ANNIE)
  16. Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.
    Crippa A, Laere B, Discacciati A, et al. · Eur Urol Oncol · 2025 · Derived
    PubMed: PMID 40263079 · NCT03903835 (ProBio)
  17. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.
    Attard G, Agarwal N, Graff JN, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41057655 · NCT04497844 (AMPLITUDE)

2024 (31 papers)

  1. Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study.
    Zhou H, Liu Q, Zhang D, et al. · Int J Gynecol Cancer · 2024 · Derived
    PubMed: PMID 39074931 · NCT04217798 · Ovarian Neoplasms
  2. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
    Yu A, Hazra A, Jiao JJ, et al. · Clin Pharmacokinet · 2024 · Derived
    PubMed: PMID 38436924 · NCT04577833 · Prostatic Neoplasms
  3. Circulating tumor DNA: from discovery to clinical application in breast cancer.
    Xu J, Gao H, Guan X, et al. · Front Immunol · 2024 · Derived
    PubMed: PMID 38745646 · NCT01042379 (I-SPY) · Breast Neoplasms
  4. PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD/E axis in ovarian cancer.
    Xia Y, Huang P, Qian YY, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39366751 · NCT04507841 · Ovarian Neoplasms
  5. Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
    Vulsteke C, Chambers SK, Pérez MJR, et al. · Eur J Cancer · 2024 · Derived
    PubMed: PMID 39013265 · NCT02655016 · Ovarian Neoplasms
  6. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Valabrega G, Pothuri B, Oaknin A, et al. · Gynecol Oncol · 2024 · Derived
    PubMed: PMID 38833992 · NCT02655016 · Ovarian Neoplasms
  7. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277672 · NCT01042379 (I-SPY) · Breast Neoplasms
  8. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer.
    Roubaud G, Attard G, Boegemann M, et al. · Eur J Cancer · 2024 · Derived
    PubMed: PMID 39111209 · NCT03748641 (MAGNITUDE) · Prostatic Neoplasms, Castration-Resistant
  9. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
    Rediti M, Venet D, Joaquin Garcia A, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39613746 · NCT01042379 (I-SPY) · Breast Neoplasms
  10. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
    Pothuri B, Han S, Chase DM, et al. · Gynecol Oncol · 2024 · Derived
    PubMed: PMID 38325276 · NCT02655016 · Ovarian Neoplasms
  11. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, et al. · J Am Med Inform Assoc · 2024 · Derived
    PubMed: PMID 39158353 · NCT01042379 (I-SPY) · Breast Neoplasms
  12. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Mutch D, Voulgari A, Chen XM, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38288862 · NCT03695380 · Ovarian Neoplasms
  13. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.
    Monk BJ, Romero I, Graybill W, et al. · Clin Ther · 2024 · Derived
    PubMed: PMID 39019698 · NCT02655016 · Ovarian Neoplasms
  14. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial.
    Liu JF, Gaillard S, Wahner Hendrickson AE, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38754056 · NCT03574779 (OPAL) · Ovarian Neoplasms
  15. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
    Li W, Partridge SC, Newitt DC, et al. · Radiol Imaging Cancer · 2024 · Derived
    PubMed: PMID 38180338 · NCT01042379 (I-SPY) · Breast Neoplasms
  16. Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity.
    Korsholm LM, Kjeldsen M, Perino L, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 38427930 · NCT02354131 (AVANOVA) · Ovarian Neoplasms
  17. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277671 · NCT01042379 (I-SPY) · Breast Neoplasms
  18. Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study.
    Itamochi H, Takeshima N, Hamanishi J, et al. · J Gynecol Oncol · 2024 · Derived
    PubMed: PMID 39058367 · NCT03759587 · Ovarian Neoplasms
  19. Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
    Graybill WS, Pardo Búrdalo B, O'Malley DM, et al. · Int J Gynecol Cancer · 2024 · Derived
    PubMed: PMID 38950925 · NCT02655016 · Ovarian Neoplasms
  20. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
    González-Martín A, Rubio MJ, Heitz F, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 39292975 · NCT03598270 (ANITA) · Ovarian Neoplasms
  21. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
    González-Martín A, Pothuri B, Vergote I, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 38501262 · NCT02655016 · Ovarian Neoplasms
  22. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  23. Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
    George TJ, Lee JH, DeRemer DL, et al. · JCO Precis Oncol · 2024 · Derived
    PubMed: PMID 39626160 · NCT03207347 · Cholangiocarcinoma
  24. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer.
    De Santis M, Breijo SM, Robinson P, et al. · Adv Ther · 2024 · Derived
    PubMed: PMID 38958846 · NCT03748641 (MAGNITUDE) · Prostatic Neoplasms, Castration-Resistant
  25. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
    De Laere B, Crippa A, Discacciati A, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39164518 · NCT03903835 (ProBio)
  26. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J, Felicetti B, Baines AJ, et al. · Trials · 2024 · Derived
    PubMed: PMID 38702828 · NCT03574779 (OPAL) · Ovarian Neoplasms
  27. Real-world patient characteristics and survival outcomes in patients with advanced or recurrent endometrial cancer in England: a retrospective, population-based study.
    Banerjee S, Ingles Russo Garces A, Garside J, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 39581729 · NCT03981796 (RUBY) · Neoplasms
  28. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Auranen A, Powell MA, Sukhin V, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 39346117 · NCT03981796 (RUBY) · Neoplasms
  29. Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.
    Aoki D, Tabata T, Yanagida S, et al. · J Gynecol Oncol · 2024 · Derived
    PubMed: PMID 39251349 · NCT03759600 · Ovarian Neoplasms
  30. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. · Ann Oncol · 2024 · Background
    PubMed: PMID 39284381 · NCT02655016 · Ovarian Neoplasms
  31. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
    Falchook G, Patnaik A, Richardson DL, et al. · Clin Ther · 2024 · Background
    PubMed: PMID 38423866 · NCT03329001 · Neoplasms

2023 (27 papers)

  1. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  2. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.
    You M, Zeng X, Zhang J, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37731489 · NCT03981796 (RUBY) · Neoplasms
  3. PIM1 is a Poor Prognostic Factor for and Potential Therapeutic Target in Serous Carcinoma of the Endometrium.
    Takeuchi H, Miyamoto T, Fuseya C, et al. · Int J Gynecol Pathol · 2023 · Derived
    PubMed: PMID 35443252 · NCT04080284 · Endometrial Neoplasms
  4. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
    Smith MR, Sandhu S, George DJ, et al. · J Manag Care Spec Pharm · 2023 · Derived
    PubMed: PMID 37404070 · NCT02854436 (Galahad) · Prostatic Neoplasms
  5. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
    Sghaier S, Corbaux P, Ray-Coquard I, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 37650734 · NCT05183984 (NIRVANA-1) · Ovarian Neoplasms
  6. Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
    Randall LM, O'Malley DM, Monk BJ, et al. · Gynecol Oncol · 2023 · Derived
    PubMed: PMID 37890345 · NCT03955471 (MOONSTONE) · Ovarian Neoplasms
  7. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, et al. · Breast Cancer Res Treat · 2023 · Derived
    PubMed: PMID 37029329 · NCT01042379 (I-SPY) · Breast Neoplasms
  8. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, et al. · Radiol Imaging Cancer · 2023 · Derived
    PubMed: PMID 37505107 · NCT01042379 (I-SPY) · Breast Neoplasms
  9. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, et al. · Ann Surg · 2023 · Derived
    PubMed: PMID 37325931 · NCT01042379 (I-SPY) · Breast Neoplasms
  10. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma.
    Morton M, Marcu I, Levine M, et al. · Obstet Gynecol · 2023 · Derived
    PubMed: PMID 37411031 · NCT03981796 (RUBY) · Neoplasms
  11. Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full?
    Montgomery B, Mostaghel EA · Eur Urol · 2023 · Derived
    PubMed: PMID 36710203 · NCT04030559 · Prostatic Neoplasms
  12. A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study.
    Liu G, Feng Y, Li J, et al. · EClinicalMedicine · 2023 · Derived
    PubMed: PMID 36583171 · NCT04376073 (ANNIE)
  13. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
    Kringelbach T, Højgaard M, Rohrberg K, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36814246 · NCT04341181 (ProTarget) · Neoplasms
  14. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
    Konstantinopoulos PA, Waggoner S, Vidal GA, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 31194228 · NCT02657889 (TOPACIO) · Ovarian Neoplasms
  15. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
    Heitz F, Marth C, Henry S, et al. · Int J Gynecol Cancer · 2023 · Derived
    PubMed: PMID 37935524 · NCT05009082 · Ovarian Neoplasms
  16. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
    González-Martín A, Pothuri B, Vergote I, et al. · Eur J Cancer · 2023 · Derived
    PubMed: PMID 37263896 · NCT02655016 · Ovarian Neoplasms
  17. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  18. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, et al. · Cell Rep Med · 2023 · Derived
    PubMed: PMID 38086377 · NCT01042379 (I-SPY) · Breast Neoplasms
  19. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37185961 · NCT02354131 (AVANOVA) · Ovarian Neoplasms
  20. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients.
    Freed IM, Kasi A, Fateru O, et al. · Cells · 2023 · Derived
    PubMed: PMID 37759489 · NCT03553004 (NIRA-PANC) · Pancreatic Neoplasms
  21. Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.
    Fennell D, Griffiths D, Eminton Z, et al. · BMJ Open · 2023 · Derived
    PubMed: PMID 37993149 · NCT05455424 (NERO) · Recurrence
  22. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Drakaki A, Powles T, Bamias A, et al. · Clin Cancer Res · 2023 · Derived
    PubMed: PMID 37651261 · NCT03869190 · Carcinoma, Transitional Cell
  23. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
    Cueva JF, Palacio I, Churruca C, et al. · Eur J Cancer · 2023 · Derived
    PubMed: PMID 36706655 · NCT04546373 · Fallopian Tube Neoplasms
  24. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
    Chi KN, Rathkopf D, Smith MR, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36952634 · NCT03748641 (MAGNITUDE) · Prostatic Neoplasms, Castration-Resistant
  25. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
    Sun K, Mikule K, Wang Z, et al. · Oncotarget · 2023 · Background
    PubMed: PMID 30647846 · NCT06258018 (ONC-2022-001) · Glioma
  26. Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.
    Mirza MR, Lindahl G, Mahner S, et al. · Cancer Res Commun · 2023 · Background
    PubMed: PMID 36970052 · NCT01847274 · Ovarian Neoplasms
  27. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR, Chase DM, Slomovitz BM, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 36972026 · NCT03981796 (RUBY) · Neoplasms

2022 (27 papers)

  1. Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.
    Zhou D, Liu J, Liu R, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 35402241 · NCT04507841 · Ovarian Neoplasms
  2. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 35623341 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  4. Postneoadjuvant treatment for triple-negative breast cancer.
    Trapani D, Ferraro E, Giugliano F, et al. · Curr Opin Oncol · 2022 · Derived
    PubMed: PMID 35993306 · NCT01042379 (I-SPY) · Breast Neoplasms
  5. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A, Ryan N, Wiggans AJ, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35170751 · NCT01847274 · Ovarian Neoplasms
  6. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34529000 · NCT01042379 (I-SPY) · Breast Neoplasms
  7. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
    Smith MR, Scher HI, Sandhu S, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35131040 · NCT02854436 (Galahad) · Prostatic Neoplasms
  8. DNA Damage Repair Inhibitors-Combination Therapies.
    Smith G, Alholm Z, Coleman RL, et al. · Cancer J · 2022 · Derived
    PubMed: PMID 34904813 · NCT04267939 · Ovarian Neoplasms
  9. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial.
    Reiss KA, Mick R, Teitelbaum U, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35810751 · NCT03404960 (Parpvax)
  10. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
    Ramalingam SS, Thara E, Awad MM, et al. · Cancer · 2022 · Derived
    PubMed: PMID 34478166 · NCT04475939 (ZEAL-1L) · Carcinoma, Non-Small-Cell Lung
  11. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    Park J, Lim MC, Lee JK, et al. · J Gynecol Oncol · 2022 · Derived
    PubMed: PMID 34910393 · NCT04734665 (NIRVANA-R) · Ovarian Neoplasms
  12. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, et al. · JAMA Surg · 2022 · Derived
    PubMed: PMID 36069821 · NCT01042379 (I-SPY) · Breast Neoplasms
  13. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
    O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, et al. · Gynecol Oncol · 2022 · Derived
    PubMed: PMID 35550709 · NCT02655016 · Ovarian Neoplasms
  14. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  15. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).
    Musacchio L, Salutari V, Pignata S, et al. · Int J Gynecol Cancer · 2022 · Derived
    PubMed: PMID 34607820 · NCT04679064 (NItCHE-MITO33) · Ovarian Neoplasms
  16. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
    Jo U, Senatorov IS, Zimmermann A, et al. · Mol Cancer Ther · 2022 · Derived
    PubMed: PMID 34045232 · NCT04149145 (PARP) · Ovarian Neoplasms
  17. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A, Sanchez Lorenzo L, Colombo N, et al. · Int J Gynecol Cancer · 2022 · Derived
    PubMed: PMID 33318079 · NCT03598270 (ANITA) · Ovarian Neoplasms
  18. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
    Fennell DA, King A, Mohammed S, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35157829 · NCT03654833 (MiST) · Mesothelioma, Malignant
  19. Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer.
    De Laere B, Crippa A, Discacciati A, et al. · Eur Urol Focus · 2022 · Derived
    PubMed: PMID 35317973 · NCT03903835 (ProBio)
  20. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
    Barretina-Ginesta MP, Monk BJ, Han S, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 36172173 · NCT02655016 · Ovarian Neoplasms
  21. Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
    Akce M, El-Khoueiry A, Piha-Paul SA, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 34324028 · NCT03359850 · Ovarian Neoplasms
  22. Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis.
    Ye L, Jia Y, Ji KE, et al. · Oncol Lett · 2022 · Background
    PubMed: PMID 26622657 · NCT05641506 · Ovarian Neoplasms
  23. IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
    Yap TA, Bessudo A, Hamilton E, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 35332062 · NCT03307785 · Neoplasms
  24. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
    Wang Y, Wild AT, Turcan S, et al. · Sci Adv · 2022 · Background
    PubMed: PMID 32494639 · NCT06258018 (ONC-2022-001) · Glioma
  25. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
    Spring LM, Han H, Liu MC, et al. · Nat Cancer · 2022 · Background
    PubMed: PMID 35788722 · NCT03329937 · Breast Neoplasms
  26. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
    Loap P, Loirat D, Berger F, et al. · JAMA Oncol · 2022 · Background
    PubMed: PMID 36301572 · NCT06329830 (LUNAAR) · Prostatic Neoplasms
  27. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Hardesty MM, Krivak TC, Wright GS, et al. · Gynecol Oncol · 2022 · Background
    PubMed: PMID 35690498 · NCT03326193 · Ovarian Neoplasms

2021 (23 papers)

  1. Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.
    Wang S, Huang HY, Wu D, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 34083331 · NCT04423185
  2. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
    Takehara K, Matsumoto T, Hamanishi J, et al. · J Gynecol Oncol · 2021 · Derived
    PubMed: PMID 33470063 · NCT03759587 · Ovarian Neoplasms
  3. Systems approach to rational combination therapy: PARP inhibitors.
    Sun C, Fang Y, Labrie M, et al. · Biochem Soc Trans · 2021 · Derived
    PubMed: PMID 32379297 · NCT03586661 · Ovarian Neoplasms
  4. A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study.
    Shi T, Yin S, Zhu J, et al. · J Gynecol Oncol · 2021 · Derived
    PubMed: PMID 32319233 · NCT03983226 · Fallopian Tube Neoplasms
  5. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
    Saad F, Chi KN, Shore ND, et al. · Cancer Chemother Pharmacol · 2021 · Derived
    PubMed: PMID 33754187 · NCT02924766 · Prostatic Neoplasms
  6. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J, Soberino J, Racca F, et al. · Expert Opin Biol Ther · 2021 · Derived
    PubMed: PMID 32450725 · NCT01042379 (I-SPY) · Breast Neoplasms
  7. Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
    Okamoto A, Kondo E, Nakamura T, et al. · J Gynecol Oncol · 2021 · Derived
    PubMed: PMID 33327047 · NCT03759600 · Ovarian Neoplasms
  8. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32053137 · NCT01042379 (I-SPY) · Breast Neoplasms
  9. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Mirza MR, Benigno B, Dørum A, et al. · Gynecol Oncol · 2021 · Derived
    PubMed: PMID 32981695 · NCT01847274 · Ovarian Neoplasms
  10. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32701140 · NCT01042379 (I-SPY) · Breast Neoplasms
  11. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
    Fennell DA, King A, Mohammed S, et al. · Lancet Respir Med · 2021 · Derived
    PubMed: PMID 33515503 · NCT03654833 (MiST) · Mesothelioma, Malignant
  12. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34741021 · NCT01042379 (I-SPY) · Breast Neoplasms
  13. The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.
    Crippa A, De Laere B, Discacciati A, et al. · Trials · 2021 · Derived
    PubMed: PMID 32586393 · NCT03903835 (ProBio)
  14. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
    Chugh R, Ballman KV, Helman LJ, et al. · Cancer · 2021 · Derived
    PubMed: PMID 33289920 · NCT02044120 · Sarcoma, Ewing
  15. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32031889 · NCT01042379 (I-SPY) · Breast Neoplasms
  16. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
    Weller M, van den Bent M, Preusser M, et al. · Nat Rev Clin Oncol · 2021 · Background
    PubMed: PMID 33293629 · NCT06258018 (ONC-2022-001) · Glioma
  17. Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
    Seyedin SN, Hasibuzzaman MM, Pham V, et al. · Int J Radiat Oncol Biol Phys · 2021 · Background
    PubMed: PMID 32036006 · NCT04926324 · Rectal Neoplasms
  18. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O, de Bono J, Chi KN, et al. · N Engl J Med · 2021 · Background
    PubMed: PMID 34161051 · NCT06329830 (LUNAAR) · Prostatic Neoplasms
  19. An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
    Romero I, Rubio MJ, Medina M, et al. · Gynecol Oncol · 2021 · Background
    PubMed: PMID 32988624 · NCT05289648 (NIREC) · Endometrial Neoplasms
  20. Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review.
    Rao VU, Reeves DJ, Chugh AR, et al. · J Am Coll Cardiol · 2021 · Background
    PubMed: PMID 34045027 · NCT06258018 (ONC-2022-001) · Glioma
  21. A therapeutic update on PARP inhibitors: implications in the treatment of glioma.
    Lal S, Snape TJ · Drug Discov Today · 2021 · Background
    PubMed: PMID 33157194 · NCT06258018 (ONC-2022-001) · Glioma
  22. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
    Hanna C, Kurian KM, Williams K, et al. · Neuro Oncol · 2021 · Background
    PubMed: PMID 32347934 · NCT06258018 (ONC-2022-001) · Glioma
  23. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
    Federico SM, Pappo AS, Sahr N, et al. · Eur J Cancer · 2021 · Background
    PubMed: PMID 32795876 · NCT06258018 (ONC-2022-001) · Glioma

2020 (10 papers)

  1. Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer.
    Zhang J, Zheng H, Gao Y, et al. · Oncologist · 2020 · Derived
    PubMed: PMID 31439812 · NCT03551171 · Ovarian Neoplasms
  2. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    Mirza MR, Bergmann TK, Mau-Sørensen M, et al. · Cancer Chemother Pharmacol · 2020 · Derived
    PubMed: PMID 31375879 · NCT02354131 (AVANOVA) · Ovarian Neoplasms
  3. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR, Åvall Lundqvist E, Birrer MJ, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 31474354 · NCT02354131 (AVANOVA) · Ovarian Neoplasms
  4. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    Matulonis UA, Walder L, Nøttrup TJ, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 31518175 · NCT01847274 · Ovarian Neoplasms
  5. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
    Färkkilä A, Gulhan DC, Casado J, et al. · Nat Commun · 2020 · Derived
    PubMed: PMID 32193378 · NCT02657889 (TOPACIO) · Ovarian Neoplasms
  6. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    Del Campo JM, Matulonis UA, Malander S, et al. · J Clin Oncol · 2020 · Derived
    PubMed: PMID 31173551 · NCT01847274 · Ovarian Neoplasms
  7. Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma.
    van den Bent MJ, Mellinghoff IK, Bindra RS, et al. · Am Soc Clin Oncol Educ Book · 2020 · Background
    PubMed: PMID 32186930 · NCT06258018 (ONC-2022-001) · Glioma
  8. Management of glioblastoma: State of the art and future directions.
    Tan AC, Ashley DM, López GY, et al. · CA Cancer J Clin · 2020 · Background
    PubMed: PMID 32478924 · NCT06258018 (ONC-2022-001) · Glioma
  9. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN, Secord AA, Geller MA, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 30948273 · NCT02354586 (QUADRA) · Ovarian Neoplasms
  10. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
    de Jonge MM, Auguste A, van Wijk LM, et al. · Clin Cancer Res · 2020 · Background
    PubMed: PMID 30413523 · NCT05289648 (NIREC) · Endometrial Neoplasms

2019 (8 papers)

  1. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM, Matulonis UA, Malander S, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 30026000 · NCT01847274 · Ovarian Neoplasms
  2. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    González-Martín A, Pothuri B, Vergote I, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31562799 · NCT02655016 · Ovarian Neoplasms
  3. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
    Galot R, Le Tourneau C, Guigay J, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 30307465 · NCT03088059 (UPSTREAM) · Squamous Cell Carcinoma of Head and Neck
  4. Safety and dose modification for patients receiving niraparib.
    Berek JS, Matulonis UA, Peen U, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 29767688 · NCT01847274 · Ovarian Neoplasms
  5. Clinical actionability of molecular targets in endometrial cancer.
    Urick ME, Bell DW · Nat Rev Cancer · 2019 · Background
    PubMed: PMID 31388127 · NCT05289648 (NIREC) · Endometrial Neoplasms
  6. Ovarian cancer statistics, 2018.
    Torre LA, Trabert B, DeSantis CE, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 29809280 · NCT05641506 · Ovarian Neoplasms
  7. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.
    Chukwueke UN, Wen PY · CNS Oncol · 2019 · Background
    PubMed: PMID 30806082 · NCT06258018 (ONC-2022-001) · Glioma
  8. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
    Bray F, Ferlay J, Soerjomataram I, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 30207593 · NCT05641506 · Ovarian Neoplasms

2018 (5 papers)

  1. [Report of Cancer Incidence and Mortality in China, 2014].
    Chen WQ, Li H, Sun KX, et al. · Zhonghua Zhong Liu Za Zhi · 2018 · Trial result
    PubMed: PMID 29365411 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  2. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, et al. · Breast Cancer Res · 2018 · Derived
    PubMed: PMID 28851423 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
    Sulkowski PL, Corso CD, Robinson ND, et al. · Sci Transl Med · 2018 · Background
    PubMed: PMID 28148839 · NCT06258018 (ONC-2022-001) · Glioma
  4. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance.
    Ramos-Esquivel A, Víquez-Jaikel Á, Fernández C, et al. · J Oncol Pract · 2018 · Background
    PubMed: PMID 28628392 · NCT05641506 · Ovarian Neoplasms
  5. The promises of immunotherapy in gliomas.
    Mildenberger I, Bunse L, Ochs K, et al. · Curr Opin Neurol · 2018 · Background
    PubMed: PMID 28984704 · NCT06258018 (ONC-2022-001) · Glioma

2017 (8 papers)

  1. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.
    van Andel L, Zhang Z, Lu S, et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2017 · Background
    PubMed: PMID 27898364 · NCT06258018 (ONC-2022-001) · Glioma
  2. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.
    Tateishi K, Higuchi F, Miller JJ, et al. · Cancer Res · 2017 · Background
    PubMed: PMID 28625978 · NCT06258018 (ONC-2022-001) · Glioma
  3. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM, Lin KK, Oza AM, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27908594 · NCT04080284 · Endometrial Neoplasms
  4. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
    Shu CA, Pike MC, Jotwani AR, et al. · JAMA Oncol · 2017 · Background
    PubMed: PMID 27367496 · NCT04080284 · Endometrial Neoplasms
  5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Pujade-Lauraine E, Ledermann JA, Selle F, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 28754483 · NCT05641506 · Ovarian Neoplasms
  6. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y, Kwintkiewicz J, Liu Y, et al. · Cancer Res · 2017 · Background
    PubMed: PMID 28202508 · NCT06258018 (ONC-2022-001) · Glioma
  7. PARP inhibitors: Synthetic lethality in the clinic.
    Lord CJ, Ashworth A · Science · 2017 · Background
    PubMed: PMID 28302823 · NCT05641506 · Ovarian Neoplasms
  8. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
    de Jonge MM, Mooyaart AL, Vreeswijk MP, et al. · Eur J Cancer · 2017 · Background
    PubMed: PMID 28049106 · NCT04080284 · Endometrial Neoplasms

2016 (7 papers)

  1. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN, Tewari KS · Clin Ther · 2016 · Trial result
    PubMed: PMID 25592089 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  2. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406347 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406346 · NCT01042379 (I-SPY) · Breast Neoplasms
  4. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
    Wang P, Wu J, Ma S, et al. · Cell Rep · 2016 · Background
    PubMed: PMID 26686626 · NCT06258018 (ONC-2022-001) · Glioma
  5. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
    Mirza MR, Monk BJ, Herrstedt J, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27717299 · NCT05641506 · Ovarian Neoplasms
  6. Germline mutations of the DNA repair pathways in uterine serous carcinoma.
    Frimer M, Levano KS, Rodriguez-Gabin A, et al. · Gynecol Oncol · 2016 · Background
    PubMed: PMID 27016235 · NCT04080284 · Endometrial Neoplasms
  7. Cancer statistics in China, 2015.
    Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26808342 · NCT04716686 · Endometrial Neoplasms

2015 (5 papers)

  1. Global cancer statistics, 2012.
    Torre LA, Bray F, Siegel RL, et al. · CA Cancer J Clin · 2015 · Trial result
    PubMed: PMID 25651787 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  2. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
    Kirstein MM, Lange A, Prenzler A, et al. · Oncologist · 2015 · Trial result
    PubMed: PMID 25326159 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  3. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA, Irshad S, Grigoriadis A, et al. · Breast Cancer Res · 2015 · Background
    PubMed: PMID 25093514 · NCT04716686 · Endometrial Neoplasms
  4. Dose-dense Temozolomide: Is It Still Promising?
    Nagane M · Neurol Med Chir (Tokyo) · 2015 · Background
    PubMed: PMID 26236801 · NCT06258018 (ONC-2022-001) · Glioma
  5. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25366685 · NCT04716686 · Endometrial Neoplasms

2014 (2 papers)

  1. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.
    Fakhrejahani E, Toi M · Jpn J Clin Oncol · 2014 · Trial result
    PubMed: PMID 24474817 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  2. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J, Harter P, Gourley C, et al. · Lancet Oncol · 2014 · Background
    PubMed: PMID 24882434 · NCT04716686 · Endometrial Neoplasms

2013 (3 papers)

  1. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma.
    Chu JS, Ge FJ, Zhang B, et al. · J Exp Clin Cancer Res · 2013 · Trial result
    PubMed: PMID 23552472 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms
  2. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma.
    Pennington KP, Walsh T, Lee M, et al. · Cancer · 2013 · Background
    PubMed: PMID 22811390 · NCT04080284 · Endometrial Neoplasms
  3. Integrated genomic characterization of endometrial carcinoma.
    Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. · Nature · 2013 · Background
    PubMed: PMID 23636398 · NCT04716686 · Endometrial Neoplasms

2012 (5 papers)

  1. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 21796368 · NCT01042379 (I-SPY) · Breast Neoplasms
  2. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, et al. · Radiology · 2012 · Trial result
    PubMed: PMID 22623692 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22649152 · NCT01042379 (I-SPY) · Breast Neoplasms
  4. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 22198468 · NCT01042379 (I-SPY) · Breast Neoplasms
  5. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA, Brady MF, Bookman MA, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22204724 · NCT06827353 (OVNI-B) · Ovarian Neoplasms

2011 (3 papers)

  1. Para-aortic lymphadenectomy in the management of preoperative grade 1 endometrial cancer confined to the uterine corpus.
    Yoon JH, Yoo SC, Kim WY, et al. · Ann Surg Oncol · 2011 · Background
    PubMed: PMID 20585865 · NCT04716686 · Endometrial Neoplasms
  2. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
    van den Bent MJ, Wefel JS, Schiff D, et al. · Lancet Oncol · 2011 · Background
    PubMed: PMID 21474379 · NCT06258018 (ONC-2022-001) · Glioma
  3. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J · JAMA · 2011 · Background
    PubMed: PMID 22187281 · NCT01042379 (I-SPY) · Breast Neoplasms

2010 (1 paper)

  1. MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
    Weller M, Stupp R, Reifenberger G, et al. · Nat Rev Neurol · 2010 · Background
    PubMed: PMID 19997073 · NCT06258018 (ONC-2022-001) · Glioma

2009 (1 paper)

  1. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, et al. · Clin Pharmacol Ther · 2009 · Background
    PubMed: PMID 19440188 · NCT01042379 (I-SPY) · Breast Neoplasms

2008 (1 paper)

  1. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
    Lamers LM, Stupp R, van den Bent MJ, et al. · Cancer · 2008 · Background
    PubMed: PMID 18213621 · NCT06258018 (ONC-2022-001) · Glioma

2005 (1 paper)

  1. The concept of synthetic lethality in the context of anticancer therapy.
    Kaelin WG · Nat Rev Cancer · 2005 · Trial result
    PubMed: PMID 16110319 · NCT04395612 (CQGOG0101) · Uterine Cervical Neoplasms

2003 (1 paper)

  1. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
    Tolcher AW, Gerson SL, Denis L, et al. · Br J Cancer · 2003 · Background
    PubMed: PMID 12671695 · NCT06258018 (ONC-2022-001) · Glioma

2001 (1 paper)

  1. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma.
    Kim H, Likhari P, Parker D, et al. · J Pharm Biomed Anal · 2001 · Background
    PubMed: PMID 11199225 · NCT06258018 (ONC-2022-001) · Glioma

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).